MedTrace Logo

A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer

NCT04308785 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-10-23

No results posted yet for this study

Summary

This is a multicenter, double-blind, placebo-controlled, randomized, phase II study to investigate the efficacy and safety of Atezolizumab with or without Tiragolumab as consolidation therapy in participants with limited stage small cell lung cancer who have not progressed during/after chemoradiotherapy.

Conditions

  • Carcinoma, Small Cell Lung

Interventions

DRUG

Atezolizumab

Atezolizumab will be administered at a dose of 1200 mg intravenously on the first day of each 21-day cycle.

DRUG

Tiragolumab

Tiragolumab will be administered at a dose of 600 mg intravenously on the first day of each 21-day cycle.

OTHER

Placebo

Placebo matching to tiragolumab will be administered at a dose of 600 mg intravenously on the first day of each cycle.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2023-07-25
Completion
2023-07-25

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04308785 on ClinicalTrials.gov